BioNTech SE (BNTX)
92.98
+0.78
(+0.85%)
USD |
NASDAQ |
May 16, 16:00
92.10
-0.88
(-0.95%)
After-Hours: 20:00
BioNTech Debt to Equity Ratio: 0.0118 for March 31, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.0118 |
| December 31, 2023 | 0.0108 |
| September 30, 2023 | 0.0102 |
| June 30, 2023 | 0.0103 |
| March 31, 2023 | 0.0104 |
| December 31, 2022 | 0.0106 |
| September 30, 2022 | 0.0149 |
| June 30, 2022 | 0.0142 |
| March 31, 2022 | 0.0117 |
| December 31, 2021 | 0.0253 |
| September 30, 2021 | 0.0329 |
| Date | Value |
|---|---|
| June 30, 2021 | 0.0468 |
| March 31, 2021 | 0.101 |
| December 31, 2020 | 0.175 |
| September 30, 2020 | 0.1893 |
| June 30, 2020 | 0.1168 |
| March 31, 2020 | 0.1487 |
| December 31, 2019 | 0.0108 |
| September 30, 2019 | 0.1629 |
| June 30, 2019 | 0.1595 |
| March 31, 2019 | |
| December 31, 2018 | 0.2037 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
0.0102
Minimum
Sep 2023
0.1893
Maximum
Sep 2020
0.0637
Average
0.0201
Median
Debt to Equity Ratio Benchmarks
| Pfizer Inc | 0.7445 |
| Moderna Inc | 0.00 |
| Novavax Inc | -0.1943 |
| GSK PLC | 1.284 |
| BioVie Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 24.04B |
| Total Liabilities (Quarterly) | 2.471B |
| Shareholders Equity (Quarterly) | 21.56B |
| Current Ratio | 11.38 |
| Net Debt Paydown Yield | -0.03% |